Clinical trial
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
NCT00257530 · Drugs for Neglected Diseases, Other · Completed
Key facts
| NCT number | NCT00257530 |
|---|---|
| Title | Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis |
| Official title | Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients |
| Lead sponsor | Drugs for Neglected Diseases, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cutaneous Leishmaniasis |
| Intervention type | Drug |
| Interventions | Imiquimod |
| Enrollment | 80 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Nov 23, 2005 |
| Last update posted | Jun 12, 2008 |
| Countries | Peru |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: